---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-014015"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:42:13.316666+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics appoints Moss Adams as auditor, reports $6.6M cash, advances DMT310 to Phase 3

## Summary
- Appointed Moss Adams LLP as new auditor for FY2023, effective Nov 9, 2023, replacing MHM.
- Cash and cash equivalents $6.6M as of Sep 30, 2023; expects to fund operations into Q2 2024.
- Received positive FDA feedback on End of Phase 2 meeting for DMT310; agreed Phase 3 program acceptable for NDA filing.
- Completed start-up activities for DMT310 Phase 3 STAR-1 trial; plans to initiate before end of 2023 after FDA protocol approval.
- Q3 2023 R&D expenses $0.9M (down from $1.6M YoY); G&A expenses flat at $0.9M.

## SEC filing metadata
- accession: 0001654954-23-014015
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 4.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/0001654954-23-014015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-014015
- JSON: https://secwatch.observer/filing/0001654954-23-014015.json
- Plain text: https://secwatch.observer/filing/0001654954-23-014015.txt

## Key facts
- Auditor Changes
  Dermata Therapeutics, Inc. engaged Moss Adams LLP as its auditor.
  - Action: engagement
  - Auditor: Moss Adams LLP
  source text: On November 9, 2023, the Audit Committee appointed Moss Adams LLP (“ Moss Adams ”) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/0001654954-23-014015-index.htm
- Earnings Releases
  Dermata Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/0001654954-23-014015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.